Drug Profile
DCDS 0780A
Alternative Names: DCDS0780ALatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Roche
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Monotherapy, Second-line therapy or greater) in USA (IV, Infusion)
- 12 Jul 2019 Phase I/Ib development for Non-Hodgkin's lymphoma is ongoing USA (NCT02453087)